{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:43:53Z","timestamp":1778910233446,"version":"3.51.4"},"reference-count":42,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1253\/circj.cj-14-0877","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T18:37:56Z","timestamp":1415731076000},"page":"161-168","source":"Crossref","is-referenced-by-count":39,"title":["Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction"],"prefix":"10.1253","volume":"79","author":[{"given":"Atsushi","family":"Izawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kashima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Ebisawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitabayashi","sequence":"additional","affiliation":[{"name":"Ina General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Nagano Chuo Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunpei","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Aizawa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Kagoshima","sequence":"additional","affiliation":[{"name":"Joetsu General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uichi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the ALPS-AMI Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jones K, Saxon L, Cunningham W, Adams P, Guideline Development Group. Secondary prevention for patients after a myocardial infarction: Summary of updated NICE guidance. <i>BMJ<\/i> 2013; 347: f6544.","DOI":"10.1136\/bmj.f6544"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. <i>J Am Coll Cardiol<\/i> 2011; 58: 2432\u20132446.","DOI":"10.1016\/j.jacc.2011.10.824"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. <i>Circulation<\/i> 2004; 110: 1061\u20131068.","DOI":"10.1161\/01.CIR.0000140261.58966.A4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? <i>Curr Opin Lipidol<\/i> 2010; 21: 298\u2013304.","DOI":"10.1097\/MOL.0b013e32833b776c"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: The Pitavastatin Heart Failure Study (PEARL Study). <i>Circ J<\/i> 2013; 77: 917\u2013925.","DOI":"10.1253\/circj.CJ-12-1062"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Oh J, Kang SM, Hong N, Youn JC, Park S, Lee SH, et al. Effect of high-dose statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure. <i>Circ J<\/i> 2014; 78: 2447\u20132454.","DOI":"10.1253\/circj.CJ-14-0670"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. <i>Am J Cardiol<\/i> 2006; 97: 1165\u20131171.","DOI":"10.1016\/j.amjcard.2005.11.031"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: Subanalysis of MUSASHI-AMI. <i>Circ J<\/i> 2007; 71: 1348\u20131353.","DOI":"10.1253\/circj.71.1348"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Steffens S, Mach F. Drug insight: Immunomodulatory effects of statins: Potential benefits for renal patients? <i>Nat Clin Pract Nephrol<\/i> 2006; 2: 378\u2013387.","DOI":"10.1038\/ncpneph0217"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. <i>J Am Coll Cardiol<\/i> 2012; 60: 1231\u20131238.","DOI":"10.1016\/j.jacc.2012.05.019"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: Weighing the evidence. <i>J Am Coll Cardiol<\/i> 2012; 60: 875\u2013881.","DOI":"10.1016\/j.jacc.2012.07.007"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee HY, Sakuma I, Ihm SH, Goh CW, Koh KK. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. <i>Circ J<\/i> 2014; 78: 281\u2013287.","DOI":"10.1253\/circj.CJ-13-1494"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sakuma I. What type of statin and what level of low-density lipoprotein cholesterol should be appropriate for secondary prevention for Japanese patients with coronary artery disease? <i>Circ J<\/i> 2012; 76: 1324\u20131325.","DOI":"10.1253\/circj.CJ-12-0503"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. <i>Lancet<\/i> 2006; 368: 1155\u20131163.","DOI":"10.1016\/S0140-6736(06)69472-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kashima Y, Izawa A, Aizawa K, Koshikawa M, Kasai H, Tomita T, et al. Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. <i>J Cardiol<\/i> 2009; 54: 76\u201379.","DOI":"10.1016\/j.jjcc.2009.04.008"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Thygesen K, Alpert JS, White HD; Joint ESC\/ACCF\/AHA\/WHF Task Force for the Redefinition of Myocardial Infarction,Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. <i>Circulation<\/i> 2007; 116: 2634\u20132653.","DOI":"10.1161\/CIRCULATIONAHA.107.187397"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome study). <i>J Am Coll Cardiol<\/i> 2009; 54: 293\u2013302.","DOI":"10.1016\/j.jacc.2009.04.033"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Miyauchi K, Daida H, Morimoto T, Hiro T, Kimura T, Nakagawa Y, et al. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy: The extended JAPAN-ACS study. <i>Circ J<\/i> 2012; 76: 825\u2013832.","DOI":"10.1253\/circj.CJ-12-0135"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: An analysis from the INTERHEART Study. <i>J Am Coll Cardiol<\/i> 2009; 53: 244\u2013253.","DOI":"10.1016\/j.jacc.2008.09.041"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lee KH, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. <i>J Am Coll Cardiol<\/i> 2011; 58: 1664\u20131671.","DOI":"10.1016\/j.jacc.2011.05.057"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. <i>N Engl J Med<\/i> 2004; 350: 1495\u20131504.","DOI":"10.1056\/NEJMoa040583"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. <i>N Engl J Med<\/i> 2005; 352: 1425\u20131435.","DOI":"10.1056\/NEJMoa050461"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Okada K, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, et al. Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: Sub-analysis of the TWINS study. <i>Circ J<\/i> 2012; 76: 1197\u20131202.","DOI":"10.1253\/circj.CJ-11-0966"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol<\/i> 2005; 46: 1425\u20131433.","DOI":"10.1016\/j.jacc.2005.05.086"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: A LDL-associated action or one more pleiotropic effect of statins? <i>Atherosclerosis<\/i> 2010; 213: 8\u201320.","DOI":"10.1016\/j.atherosclerosis.2010.04.032"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) study. <i>Circulation<\/i> 2007; 115: 576\u2013583.","DOI":"10.1161\/CIRCULATIONAHA.106.625574"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets TNT study). <i>Am J Cardiol<\/i> 2012; 109: 1761\u20131766.","DOI":"10.1016\/j.amjcard.2012.02.019"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. <i>Atherosclerosis<\/i> 2009; 206: 512\u2013517.","DOI":"10.1016\/j.atherosclerosis.2009.03.031"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, Shiwaku HO, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. <i>J Am Soc Nephrol<\/i> 2009; 20: 2546\u20132555.","DOI":"10.1681\/ASN.2009070696"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. <i>Fundam Clin Pharmacol<\/i> 2005; 19: 117\u2013125.","DOI":"10.1111\/j.1472-8206.2004.00299.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ichihara K, Satoh K, Abiko Y. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. <i>J Cardiovasc Pharmacol<\/i> 1993; 22: 852\u2013856.","DOI":"10.1097\/00005344-199312000-00012"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. <i>J Cardiovasc Pharmacol<\/i> 2000; 35: 256\u2013262.","DOI":"10.1097\/00005344-200002000-00012"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. <i>J Am Coll Cardiol<\/i> 2002; 40: 1609\u20131614.","DOI":"10.1016\/S0735-1097(02)02340-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kim MC, Ahn Y, Jang SY, Cho KH, Hwang SH, Lee MG, et al. Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. <i>Korean J Intern Med<\/i> 2011; 26: 294\u2013303.","DOI":"10.3904\/kjim.2011.26.3.294"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hirayama S, Nakagawa S, Soda S, Kamimura Y, Nishioka E, Ueno T, et al. Ezetimibe decreases serum oxidized cholesterol without impairing bile acid synthesis in Japanese hypercholesterolemic patients. <i>Atherosclerosis<\/i> 2013; 230: 48\u201351.","DOI":"10.1016\/j.atherosclerosis.2013.06.016"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Okada K, Iwahashi N, Endo T, Himeno H, Fukui K, Kobayashi S, et al. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. <i>Atherosclerosis<\/i> 2012; 224: 454\u2013456.","DOI":"10.1016\/j.atherosclerosis.2012.07.036"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: Results of a pilot study. <i>J Cardiovasc Pharmacol Ther<\/i> 2013; 18: 5\u201312.","DOI":"10.1177\/1074248412445506"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Lin CF, Gau CS, Wu FL, Hsiao FY, Bai CH, Shen LJ. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: A 3-year population-based retrospective cohort study in Taiwan. <i>Clin Ther<\/i> 2011; 33: 1120\u20131131.","DOI":"10.1016\/j.clinthera.2011.08.002"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. <i>N Engl J Med<\/i> 2008; 358: 1431\u20131443.","DOI":"10.1056\/NEJMoa0800742"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. <i>N Engl J Med<\/i> 2009; 361: 2113\u20132122.","DOI":"10.1056\/NEJMoa0907569"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ijioma N, Robinson JG. Lipid-lowering effects of ezetimibe and simvastatin in combination. <i>Expert Rev Cardiovasc Ther<\/i> 2011; 9: 131\u2013145.","DOI":"10.1586\/erc.10.179"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. <i>Lancet<\/i> 2010; 375: 735\u2013742.","DOI":"10.1016\/S0140-6736(09)61965-6"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/79\/1\/79_CJ-14-0877\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T19:59:38Z","timestamp":1498161578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/79\/1\/79_CJ-14-0877\/_article"}},"subtitle":["\u2013 ALPS-AMI Study \u2013"],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-14-0877","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}